Financials

  • Market Capitalization 13.13 M
  • Employee 6
  • Founded 2011
  • CEO N/A
  • Website www.phiopharma.com
  • Headquarter Delaware, United States
  • FIGI BBG0024FKD97
  • Industry 生物技术
总收入
净利润
每股基本收益(基本 EPS)
总债务
自由现金流
现金及现金等价物
市盈率
-0.72
市销率

Related tickers

#姓名价格24小时 %7天 %一个月 %一年 %市值最近7天
4700
GTBP
GT Biopharma, Inc. - Common Stock
0.30 USD0.00%+3.45%0.00%-67.74%13.53 M USD
4703
KALA
KALA BIO, Inc. - Common Stock
0.69 USD-13.75%-15.85%0.00%-94.25%13.34 M USD
4713
MBRX
Moleculin Biotech, Inc. - Common Stock
0.65 USD-5.80%+8.33%-51.13%-79.37%12.66 M USD
4724
QNRX
Quoin Pharmaceuticals Ltd - American Depositary Shares
6.12 USD+18.60%+13.33%+45.37%-34.33%12.29 M USD

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharmaceuticals Corporation 是一家美国临床阶段的生物技术公司,致力于在免疫肿瘤学领域开发其 INTASYL siRNA 疗法。该公司前身为 RXi Pharmaceuticals,于 2018 年更名为 Phio Pharmaceuticals。

新闻